How HCA Healthcare, Inc. Makes Money

HCA Healthcare generates revenue by providing acute care hospital services, outpatient surgical procedures, emergency room care, and ancillary healthcare services to patients across its network of approximately 190 hospitals and 2,400 sites of care. Revenue flows through four primary channels: inpatient hospital admissions, outpatient services, emergency department visits, and ancillary services including diagnostic imaging, laboratory testing, and pharmacy. In FY2024, inpatient services accounted for approximately 62.2% of revenue ($43.9 billion), while outpatient services contributed 37.8% ($26.7 billion). The company does not report formal business segments; instead, operations are managed through geographically organized divisions and local markets, with financial results aggregated at the corporate level. Revenue is recognized when services are rendered to patients, with the amount dependent on the payer type, negotiated rates, and the complexity of care delivered. The payer mix in 2024 was estimated at 45% managed care/commercial insurance ($31.8 billion), 30% Medicare ($21.2 billion), 10% Medicaid ($7.1 billion), 8% self-pay/uninsured ($5.6 billion), and 7% other ($4.9 billion). Managed care admissions grew 9.2% in Q4 2024, reflecting strong commercial volume trends, while exchange (ACA) volume represented 7.5% of adjusted admissions and 9% of revenue. Medicare and Medicaid reimbursement rates are set by federal and state governments, creating pricing pressure that HCA offsets through volume growth, acuity mix management, and operational efficiency. Commercial insurance rates are negotiated annually, with HCA reporting that it was 80% contracted for 2025 and 60% contracted for 2026 as of early 2025, with mid-single-digit rate escalators typical for renewals. Revenue per equivalent admission was $17,695 in 2024, up 3.2% from $17,149 in 2023, driven by improved payer mix and higher acuity cases. The company's cost structure is dominated by labor, with salaries and benefits representing approximately 45.4% of revenue ($32.1 billion estimated for 2024). Supply costs represent the second-largest expense category, followed by professional fees, depreciation, and interest expense. HCA operates its own group purchasing organization, HealthTrust, which leverages the purchasing volume of approximately 1,600 hospitals and 37,000 non-acute care sites to negotiate favorable pricing on pharmaceuticals, medical devices, and supplies. This scale advantage reduces per-unit costs and provides a competitive moat that smaller hospital systems cannot replicate. The company's ambulatory network includes 124 freestanding ambulatory surgery centers, 26 endoscopy centers, approximately 100 urgent care facilities, and approximately 50 freestanding emergency rooms. These outpatient facilities generate higher margins than inpatient care and capture the industry-wide shift toward lower-cost settings. HCA's capital allocation strategy prioritizes organic growth through bed additions, de novo hospital construction, and ambulatory expansion; maintenance capital expenditures to preserve existing facilities; strategic tuck-in acquisitions to fill geographic gaps; and shareholder returns through dividends and share repurchases. In 2024, capital expenditures totaled $4.9 billion, share repurchases were $6.04 billion, and dividends were $599 million. The company maintains a target leverage range of 2.75x–3.75x net debt to adjusted EBITDA, using debt financing to fund growth while generating sufficient cash flow from operations ($10.5 billion in 2024) to service interest ($2.06 billion) and return capital to shareholders.

HCA Healthcare's growth strategy under CEO Sam Hazen emphasizes organic network development, operational efficiency, and disciplined capital allocation rather than large-scale acquisitions. The first pillar, organic network development, involves adding hospital beds, building de novo hospitals in high-growth Sun Belt markets, and expanding the ambulatory care network. In 2024, HCA increased its facility/site of care count by 3.3% to approximately 2,750 and added approximately 2% to inpatient bed capacity. The company has a multi-year capital pipeline of $5.5–$6 billion in approved projects, with 2025 capital expenditures guided at $5.0–$5.2 billion. The second pillar, operational efficiency, targets $400 million in cost savings through a resiliency plan that leverages digital transformation and AI. Specific initiatives include AI-driven clinical documentation to reduce physician administrative burden, nursing handoff protocols to improve care transitions, case management optimization to reduce length of stay, and revenue cycle automation to improve collections. In Q1 2025, labor costs as a percentage of revenue improved 80 basis points year-over-year, and supply costs improved 30 basis points, demonstrating early progress. The third pillar, workforce development, addresses the nursing shortage through Galen College of Nursing expansion, partnerships with external nursing schools, nurse residency programs, and competitive compensation packages. The company employed approximately 93,000 nurses in 2024 and has made workforce stability a strategic priority. The fourth pillar, capital allocation discipline, balances growth investments with shareholder returns. In 2024, HCA deployed $4.9 billion in capital expenditures, $6.04 billion in share repurchases, and $599 million in dividends. The company lowered its targeted leverage range to 2.75x–3.75x from 3x–4x, reflecting confidence in cash flow stability and a desire to maintain investment-grade credit access. Management has indicated that 2025 will focus on organic growth rather than transformative M&A, though tuck-in acquisitions of ambulatory facilities, urgent care centers, and physician practices will continue to fill geographic gaps and strengthen market density.